Senju Pharmaceutical Co., Ltd.

Yasuko Umegaki

Kazumi Ogata

Takahiro Sakaue

Shinji Ohmori

Hideki Tsuruoka

Rie Nagao

Yuuichi Isowaki

Yasushi Okumura

Katsuichi Sudo

An ophthalmic preparation which comprises a fumagillol derivative represented by the general formula(I): ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is a halogen, N(O).sub.m R.sup.5 R.sup.6, N.sup.+ R.sup.5 R.sup.6 R.sup.7 .multidot.X.sup.-, S(O).sub.n R.sup.5 or S.sup.+ R.sup.5 R.sup.6 .multidot.X.sup.-, wherein R.sup.5, R.sup.6 and R.sup.7 represent independently a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted heterocyclic group; X.sup.- represents a counter anion; m represents 0 or 1; n represents an integer from 0 to 2; or R.sup.5 and R.sup.6 together with the adjacent nitrogen or sulfur atom may form a substituted or unsubstituted nitrogen- or sulfur-containing heterocyclic group which may form a condensed ring; or R.sup.1 and R.sup.2 are combined to represent a chemical bond; R.sup.3 is a substituted or unsubstituted 2-methyl-l-propenyl group or a substituted or unsubstituted isobutyl group; A is oxygen or NR.sup.8, wherein R.sup.8 represents hydrogen, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted aryl group; and R.sup.4 is hydrogen, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group and a salt thereof is useful for inhibiting corneal opacification occurring after ophthalmic surgery.

Corneal opacification inhibitory composition

This invention relates to a lipid metabolism improving medicinal composition containing a phosphoric acid diester compound of the formula or a pharmacologically acceptable salt thereof. ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group. The lipid metabolism improving medicinal composition of this invention lowers the plasma levels of triglycerides (TG), non-esterified fatty acids (NEFA), total cholesterol (T-ch), esterified cholesterol (E-ch), free cholesterol (F-ch), total lipid (TL) and lipid peroxides (LPO) and, among cholesterol fractions, increases the high-density lipoprotein (HDL) fraction and reduces the low-density ipoprotein (VLDL) fractions. Therefore, the composition can be used with advantage for the amelioration of hyperlipidemia associated with arteriosclerotic diseases such as myocardial infarction, angina pectoris, cerebral infarction, cerebral arteriosclerosis, etc., nephrosis, hypertension, diabetes, obesity and other diseases and for the prophylaxis of various cerebrovascular diseases.

Lipid metabolism improving medicinal composition

A method of lowering lipids is disclosed wherein a patient is administered a lipid metabolism improving composition characterized by comprising a compound of the following formula: ##STR1## wherein R.sub.1 represents a hydrogen atom or a lower alkyl group; R.sub.2 and R.sub.3 are the same or different and each represents a hydroxyl group, a lower alkoxy group or an amino group, or a pharmacologically acceptable salt thereof as an active ingredient. Since the compound of the present invention lowers blood triglyceride, cholesterol and .beta.-lipoprotein levels, it is of value for ameliorating hyperlipidemia in arteriosclerotic diseases, e.g. myocardinal infarction, angina pectoris, cerebral infarction, cerebral arteriosclerosis, etc., nephrosis, hypertension, diabetes, obesity and other diseases, and prevention of various circulatory diseases.

Method of lowering lipids

Growing community of inventors

Kobe, Japan

Yasuko Umegaki